The pathogenesis of neonatal autoimmune and autoinflammatory diseases: A comprehensive review

Journal of Autoimmunity

Volumn 41, Issue , 2013, Pages 100-110

  Chang, Christopher ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Apoptosis; Autoinflammatory syndromes; CAPS; CINCA; Congenital heart block; Cryopyrin associated periodic syndromes; Cutaneous lupus erythematosus; IL18; IL1beta; Inflammasome; Muckle Wells syndrome; NALP3; Neonatal autoimmunity; Neonatal lupus; NOMID; Periodic fever syndromes; UDA syndrome

Indexed keywords

HOST FACTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CELL MATURATION; CHROMOSOME 1; CINCA SYNDROME; CROSS REACTION; DISEASE SEVERITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE; GENETIC PREDISPOSITION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEREDITY; HUMAN; INCIDENCE; INNATE IMMUNITY; LUPUS LIKE SYNDROME; MICROCHIMERISM; MOLECULAR MIMICRY; MUCKLE WELLS SYNDROME; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFANT, NEWBORN; INFLAMMASOMES; MUTATION;

EID: 84875950168     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.12.010     Document Type: Review

References (120)

1. Abrahams V.M., Borghi M.O., Meroni P.L., Rand J.H., Raschi E.R., Salmon J.E., et al. What is the mechanism(s) of antiphospholipid antibody-mediated pregnancy morbidity?. Antiphospholipid syndrome: insights and highlights from the 13th international congress on antiphospholipid antibodies 2012, 79-101. Springer Science+Business Media, New York. D. Erkan, S.S. Pierangeli (Eds.).
2. Cervera R., Balasch J. Autoimmunity and recurrent pregnancy losses. Clin Rev Allergy Immunol 2010, 39:148-152.
3. Ambrosio P., Lermann R., Cordeiro A., Borges A., Nogueira I., Serrano F. Lupus and pregnancy-15 years of experience in a tertiary center. Clin Rev Allergy Immunol 2010, 38:77-81.
4. Carp H.J., Selmi C., Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012, 38:J266-J274.
5. Chang C. Neonatal autoimmune diseases. Lupus 2012, 21:1487-1491.
6. Chang C. Neonatal autoimmune diseases: a critical review. J Autoimmun 2012, 38:J223-J238.
7. Lee L.A. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev 2005, 4:207-213.
8. Hon K.L., Leung A.K. Neonatal lupus erythematosus. Autoimmune Dis 2012, 2012:301274.
9. Morquio L. Sur une maladie infantile et familale characterisee par des modifications permanentes du pouls, des attaques syncopales et epileptiformes, et al mort subite. Arch Med Inf 1901, 4:467-475.
10. Hull D., Binns B.A., Joyce D. Congenital heart block and widespread fibrosis due to maternal lupus erythematosus. Arch Dis Child 1966, 41:688-690.
11. Chameides L., Truex R.C., Vetter V., Rashkind W.J., Galioto F.M., Noonan J.A. Association of maternal systemic lupus erythematosus with congenital complete heart block. N Engl J Med 1977, 297:1204-1207.
12. Esscher E., Scott J.S. Congenital heart block and maternal systemic lupus erythematosus. Br Med J 1979, 1:1235-1238.
13. McCue C.M., Mantakas M.E., Tingelstad J.B., Ruddy S. Congenital heart block in newborns of mothers with connective tissue disease. Circulation 1977, 56:82-90.
14. Alspaugh M.A., Talal N., Tan E.M. Differentiation and characterization of autoantibodies and their antigens in Sjogren's syndrome. Arthritis Rheum 1976, 19:216-222.
15. Harley J.B., Kaine J.L., Fox O.F., Reichlin M., Gruber B. Ro (SS-A) antibody and antigen in a patient with congenital complete heart block. Arthritis Rheum 1985, 28:1321-1325.
16. Reed B.R., Lee L.A., Harmon C., Wolfe R., Wiggins J., Peebles C., et al. Autoantibodies to SS-A/Ro in infants with congenital heart block. J Pediatr 1983, 103:889-891.
17. Deng J.S., Sontheimer R.D., Gilliam J.N. Expression of Ro/SS-A antigen in human skin and heart. J Invest Dermatol 1985, 85:412-416.
18. Kuo T.T., Baker K., Yoshida M., Qiao S.W., Aveson V.G., Lencer W.I., et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010, 30:777-789.
19. Kristoffersen E.K., Matre R. Co-localization of the neonatal Fc gamma receptor and IgG in human placental term syncytiotrophoblasts. Eur J Immunol 1996, 26:1668-1671.
20. Ward E.S., Ober R.J. Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol 2009, 103:77-115.
21. Rath T., Kuo T.T., Baker K., Qiao S.W., Kobayashi K., Yoshida M., et al. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013, 33(Suppl 1):9-17.
22. Baker K., Qiao S.W., Kuo T.T., Aveson V.G., Platzer B., Andersen J.T., et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A 2011, 108:9927-9932.
23. Cresswell P., Ackerman A.L., Giodini A., Peaper D.R., Wearsch P.A. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol Rev 2005, 207:145-157.
24. Amigorena S., Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 2010, 22:109-117.
25. Lindop R., Arentz G., Thurgood L.A., Reed J.H., Jackson M.W., Gordon T.P. Pathogenicity and proteomic signatures of autoantibodies to Ro and La. Immunol Cell Biol 2012, 90:304-309.
26. Kobayashi R., Mii S., Nakano T., Harada H., Eto H. Neonatal lupus erythematosus in Japan: a review of the literature. Autoimmun Rev 2009, 8:462-466.
27. Wei S., Yuan T.M., Chen L.H., Yu H.M. Neonatal lupus erythematosus: three case reports and review of the Chinese literature. Clin Pediatr (Phila) 2010, 49:627-634.
28. Izmirly P.M., Saxena A., Kim M.Y., Wang D., Sahl S.K., Llanos C., et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011, 124:1927-1935.
29. Wolin S.L., Steitz J.A. The Ro small cytoplasmic ribonucleoproteins: identification of the antigenic protein and its binding site on the Ro RNAs. Proc Natl Acad Sci U S A 1984, 81:1996-2000.
30. Yukiko N. Immune responses to SS-A 52-kDa and 60-kDa proteins and to SS-B 50-kDa protein in mothers of infants with neonatal lupus erythematosus. Br J Dermatol 2000, 142:908-912.
31. Oke V., Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 2012, 39:77-82.
32. Defendenti C., Atzeni F., Spina M.F., Grosso S., Cereda A., Guercilena G., et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154.
33. Buyon J.P., Winchester R.J., Slade S.G., Arnett F., Copel J., Friedman D., et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993, 36:1263-1273.
34. Llanos C., Izmirly P.M., Katholi M., Clancy R.M., Friedman D.M., Kim M.Y., et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009, 60:3091-3097.
35. Reed J.H., Jackson M.W., Gordon T.P. B cell apotopes of the 60-kDa Ro/SSA and La/SSB autoantigens. J Autoimmun 2008, 31:263-267.
36. Reed J.H., Clancy R.M., Purcell A.W., Kim M.Y., Gordon T.P., Buyon J.P. Beta2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. J Immunol 2011, 187:520-526.
37. Izmirly P.M., Buyon J.P., Saxena A. Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol 2012, 24:466-472.
38. de la Torre Y.M., Pregnolato F., D'Amelio F., Grossi C., Di Simone N., Pasqualini F., et al. Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 2012, 38:J209-J215.
39. Hu K., Qu Y., Yue Y., Boutjdir M. Functional basis of sinus bradycardia in congenital heart block. Circ Res 2004, 94:e32-e38.
40. Boutjdir M. Molecular and ionic basis of congenital complete heart block. Trends Cardiovasc Med 2000, 10:114-122.
41. Strandberg L., Winqvist O., Sonesson S.E., Mohseni S., Salomonsson S., Bremme K., et al. Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 2008, 154:30-37.
42. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
43. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
44. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008, 105:19571-19578.
45. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
46. Buyon J.P., Clancy R.M., Friedman D.M. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009, 5:139-148.
47. Friedman D.M., Llanos C., Izmirly P.M., Brock B., Byron J., Copel J., et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010, 62:1138-1146.
48. Adams Waldorf K.M., Nelson J.L. Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy. Immunol Invest 2008, 37:631-644.
49. Stevens A.M., Hermes H.M., Rutledge J.C., Buyon J.P., Nelson J.L. Myocardial-tissue-specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 2003, 362:1617-1623.
50. Stevens A.M., Hermes H.M., Lambert N.C., Nelson J.L., Meroni P.L., Cimaz R. Maternal and sibling microchimerism in twins and triplets discordant for neonatal lupus syndrome-congenital heart block. Rheumatology (Oxford) 2005, 44:187-191.
51. Adams K.M., Yan Z., Stevens A.M., Nelson J.L. The changing maternal "self" hypothesis: a mechanism for maternal tolerance of the fetus. Placenta 2007, 28:378-382.
52. Roy E., Leduc M., Guegan S., Rachdi L., Kluger N., Scharfmann R., et al. Specific maternal microchimeric T cells targeting fetal antigens in beta cells predispose to auto-immune diabetes in the child. J Autoimmun 2011, 36:253-262.
53. Schatorje E.J., Gemen E.F., Driessen G.J., Leuvenink J., van Hout R.W., de Vries E. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol 2012, 75:436-444.
54. Setiady Y.Y., Agersborg S., Samy E.T., Lewis J.E., Tung K.S. Neonatal autoimmune disease: influence of CD4+ CD25+ regulatory T cells. Int Rev Immunol 2005, 24:227-245.
55. Walk J., Westerlaken G.H., van Uden N.O., Belderbos M.E., Meyaard L., Bont L.J. Inhibitory receptor expression on neonatal immune cells. Clin Exp Immunol 2012, 169:164-171.
56. Guerrier T., Le Pottier L., Devauchelle V., Pers J.O., Jamin C., Youinou P. Role of toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues. J Autoimmun 2012, 39:69-76.
57. Santiago-Raber M.L., Baudino L., Alvarez M., van Rooijen N., Nimmerjahn F., Izui S. TLR7/9-mediated monocytosis and maturation of Gr-1(hi) inflammatory monocytes towards Gr-1(lo) resting monocytes implicated in murine lupus. J Autoimmun 2011, 37:171-179.
58. Alvarez D., Briassouli P., Clancy R.M., Zavadil J., Reed J.H., Abellar R.G., et al. A novel role of endothelin-1 in linking toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem 2011, 286:30444-30454.
59. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C.N., Khamashta M.A., Kim M.Y., Saxena A., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012, 126:76-82.
60. Chang C., Gershwin M.E. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011, 34:357-374.
61. Fehr E.M., Spoerl S., Heyder P., Herrmann M., Bekeredjian-Ding I., Blank N., et al. Apoptotic-cell-derived membrane vesicles induce an alternative maturation of human dendritic cells which is disturbed in SLE. J Autoimmun 2012 Sep 29., [Epub ahead of print].
62. Tischner D., Gaggl I., Peschel I., Kaufmann M., Tuzlak S., Drach M., et al. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J Autoimmun 2012, 38:59-69.
63. Paunovic V., Carter N.A., Thalhamer T., Blair D., Gordon B., Lacey E., et al. Immune complex-mediated co-ligation of the BCR with FcgammaRIIB results in homeostatic apoptosis of B cells involving Fas signalling that is defective in the MRL/Lpr model of systemic lupus erythematosus. J Autoimmun 2012, 39:332-346.
64. Lee L.A., Lillis P.J., Fritz K.A., Huff J.C., Norris D.A., Weston W.L. Neonatal lupus syndrome in successive pregnancies. J Am Acad Dermatol 1983, 9:401-406.
65. Lee L.A., Bias W.B., Arnett F.C., Huff J.C., Norris D.A., Harmon C., et al. Immunogenetics of the neonatal lupus syndrome. Ann Intern Med 1983, 99:592-596.
66. Siren M.K., Julkunen H., Kaaja R., Ekblad H., Koskimies S. Role of HLA in congenital heart block: susceptibility alleles in children. Lupus 1999, 8:60-67.
67. Clancy R.M., Marion M.C., Kaufman K.M., Ramos P.S., Adler A., Harley J.B., et al. Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. Arthritis Rheum 2010, 62:3415-3424.
68. Ramos P.S., Marion M.C., Langefeld C.D., Buyon J.P., Clancy R.M. Enrichment of associations in genes with fibrosis, apoptosis, and innate immunity functions with cardiac manifestation of neonatal lupus. Arthritis Rheum 2012, 64:4060-4065.
69. Cherian T.S., Kariuki S.N., Franek B.S., Buyon J.P., Clancy R.M., Niewold T.B. Brief report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupus. Arthritis Rheum 2012, 64:3383-3387.
70. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. J Autoimmun 2012, 39:249-252.
71. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a national institute of environmental health sciences expert panel workshop. J Autoimmun 2012, 39:272-284.
72. Witherpoon F.G., White C.B., Bazemore J.M., Hailey H. Familial urticaria dur to cold. Arch Derm Syphilol 1948, 58:52-55.
73. Muckle T.J., Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962, 31:235-248.
74. Lorber J. Syndrome for diagnosis: dwarfing, persistently open fontanelle; recurrent meningitis; recurrent subdural effusions with temporary alternate-sided hemiplegia; high-tone deafness; visual defect with pseudopapilloedema; slowing intellectual development; recurrent acute polyarthritis; erythema marginatum, splenomegaly and iron-resistant hypochromic anaemia. Proc R Soc Med 1973, 66:1070-1071.
75. Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
76. Neven B., Prieur A.M., Quartier dit Maire P. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008, 4:481-489.
77. Hawkins P.N., Lachmann H.J., Aganna E., McDermott M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50:607-612.
78. Torbiak R.P., Dent P.B., Cockshott W.P. NOMID-a neonatal syndrome of multisystem inflammation. Skeletal Radiol 1989, 18:359-364.
79. Montealegre Sanchez G.A., Hashkes P.J. Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes. Dev Med Child Neurol 2009, 51:420-428.
80. Savic S., Dickie L.J., Battellino M., McDermott M.F. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases. Curr Opin Rheumatol 2012, 24:103-112.
81. Vergara C., Borzutzky A., Gutierrez M.A., Iacobelli S., Talesnik E., Martinez M.E., et al. Clinical and genetic features of hereditary periodic fever syndromes in Hispanic patients: the Chilean experience. Clin Rheumatol 2012, 31:829-834.
82. Sfriso P., Caso F., Tognon S., Galozzi P., Gava A., Punzi L. Blau syndrome, clinical and genetic aspects. Autoimmun Rev 2012, 12:44-51.
83. Cantarini L., Lucherini O.M., Muscari I., Frediani B., Galeazzi M., Brizi M.G., et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 2012, 12:38-43.
84. Korppi M., Van Gijn M.E., Antila K. Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr 2011, 100:21-25.
85. Lee H., Park S.H., Kim S.K., Choe J.Y., Park J.S. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab. Clin Exp Rheumatol 2012, 30:452.
86. Hoffman H.M., Wright F.A., Broide D.H., Wanderer A.A., Kolodner R.D. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am J Hum Genet 2000, 66:1693-1698.
87. Ting J.P., Davis B.K. CATERPILLER: a novel gene family important in immunity, cell death, and diseases. Annu Rev Immunol 2005, 23:387-414.
88. Koonin E.V., Aravind L. The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. Trends Biochem Sci 2000, 25:223-224.
89. Hoffman H.M., Wanderer A.A., Broide D.H. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001, 108:615-620.
90. Aksentijevich I., Nowak M., Mallah M., Chae J.J., Watford W.T., Hofmann S.R., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46:3340-3348.
91. Lich J.D., Arthur J.C., Ting J.P. Cryopyrin: in from the cold. Immunity 2006, 24:241-243.
92. Plantinga T.S., Crisan T.O., Oosting M., van de Veerdonk F.L., de Jong D.J., Philpott D.J., et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 2011, 60:1229-1235.
93. de Jong B.A., Huizinga T.W., Bollen E.L., Uitdehaag B.M., Bosma G.P., van Buchem M.A., et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002, 126:172-179.
94. Attur M., Belitskaya-Levy I., Oh C., Krasnokutsky S., Greenberg J., Samuels J., et al. Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum 2011, 63:1908-1917.
95. Geldhoff M., Mook-Kanamori B.B., Brouwer M.C., Valls Seron M., Baas F., van der Ende A., et al. Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. Immunogenetics 2013, 65:9-16.
96. Kone-Paut I., Piram M. Targeting interleukin-1beta in CAPS (cryopyrin-associated periodic) syndromes: what did we learn?. Autoimmun Rev 2012, 12:77-80.
97. Blech M., Peter D., Fischer P., Bauer M., Hafner M., Zeeb M., et al. One target - two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1beta (IL-1beta). J Mol Biol 2013, 425:94-111.
98. Marleau A.M., Sarvetnick N.E. IL-18 is required for self-reactive T cell expansion in NOD mice. J Autoimmun 2011, 36:263-277.
99. Volin M.V., Koch A.E. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res 2011, 31:745-751.
100. Franchi L., Eigenbrod T., Munoz-Planillo R., Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009, 10:241-247.
101. Lamkanfi M., Dixit V.M. The inflammasomes. PLoS Pathog 2009, 5:e1000510.
102. Lamkanfi M., Dixit V.M. Inflammasomes: guardians of cytosolic sanctity. Immunol Rev 2009, 227:95-105.
103. Mariathasan S. ASC, Ipaf and cryopyrin/Nalp3: bona fide intracellular adapters of the caspase-1 inflammasome. Microbes Infect 2007, 9:664-671.
104. Ozkurede V.U., Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol 2012, 167:382-390.
105. Bonar S.L., Brydges S.D., Mueller J.L., McGeough M.D., Pena C., Chen D., et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One 2012, 7:e35979.
106. Muruve D.A., Petrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452:103-107.
107. Sutterwala F.S., Ogura Y., Szczepanik M., Lara-Tejero M., Lichtenberger G.S., Grant E.P., et al. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006, 24:317-327.
108. Kanneganti T.D., Ozoren N., Body-Malapel M., Amer A., Park J.H., Franchi L., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006, 440:233-236.
109. Kanneganti T.D., Body-Malapel M., Amer A., Park J.H., Whitfield J., Franchi L., et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem 2006, 281:36560-36568.
110. Pelegrin P., Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem 2007, 282:2386-2394.
111. Kanneganti T.D., Lamkanfi M., Kim Y.G., Chen G., Park J.H., Franchi L., et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of toll-like receptor signaling. Immunity 2007, 26:433-443.
112. Mariathasan S., Weiss D.S., Newton K., McBride J., O'Rourke K., Roose-Girma M., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006, 440:228-232.
113. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
114. Dostert C., Petrilli V., Van Bruggen R., Steele C., Mossman B.T., Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008, 320:674-677.
115. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
116. Cassel S.L., Eisenbarth S.C., Iyer S.S., Sadler J.J., Colegio O.R., Tephly L.A., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008, 105:9035-9040.
117. Fink S.L., Bergsbaken T., Cookson B.T. Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc Natl Acad Sci U S A 2008, 105:4312-4317.
118. Franchi L., Kanneganti T.D., Dubyak G.R., Nunez G. Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem 2007, 282:18810-18818.
119. Petrilli V., Papin S., Dostert C., Mayor A., Martinon F., Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589.
120. Wittkowski H., Kuemmerle-Deschner J.B., Austermann J., Holzinger D., Goldbach-Mansky R., Gramlich K., et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis 2011, 70:2075-2081.